SAFETY OF USTEKINUMAB IN OLDER IBD PATIENTS (>=60 YEARS): POOLED SAFETY ANALYSIS THROUGH 5 YEARS IN CD AND 2 YEARS IN UC AND ALL APPROVED INDICATIONS

Subrata Ghosh  ¹     Elyssa Ott  ²     Christopher Gasink  ²     Ye Miao  ³     John Lynch  ³     Aline Charabaty  ⁴     Colleen W. Marano  ⁴     Maria T. Abreu  ^5    
1 University of Birmingham, Birmingham, United Kingdom
² Janssen Scientific Affairs, LLC, Horsham, United States
³ Janssen Research & Development, LLC, Spring House, United States
⁴ Johns Hopkins School of Medicine, Washington, D.C., United States
⁵ University of Miami Miller School of Medicine, Miami, United States

Topic
IBD

Session
Safety and outcomes of interventions in IBD

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)